Targeting neurodegenerative diseases using risuteganib

Video


Dr Glenn J. Jaffe, professor of ophthalmology, Dr Robert Machemer, Distinguished Professor of Ophthalmology, Chief, Division of Retinal Ophthalmology at the Duke University School of Medicine, discusses the key points of his virtual presentation," Risuteganib Modulates Multiple Transcription Factors regulated by Hydroquinone in Human RPE Cells (Allegro)," including targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised and the need for newer treatment therapies to target different pathways.

See more ARVO content

Related Videos
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Scott D Barnes, MD, CMO of STAAR Surgical
Greg Kunst, CEO of Aurion Biotech
Thomas Bosshard stands at the Oertli Instruments booth at the ESCRS meeting
© 2023 MJH Life Sciences

All rights reserved.